Analyst Rating Update on Pacira Pharmaceuticals (PCRX)

Pacira Pharmaceuticals (PCRX) : Zacks Investment Research ranks Pacira Pharmaceuticals (PCRX) as 3, which is a Hold recommendation. 6 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 8 research analysts is 1.5, which indicates as a Strong Buy.

Pacira Pharmaceuticals (PCRX) : The most positive equity analysts on Pacira Pharmaceuticals (PCRX) expects the shares to touch $105, whereas, the least positive believes that the stock will trade at $59 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $77.13 with an expected fluctuation of $14.04 from the mean.

For the current week, the company shares have a recommendation consensus of Buy.


Pacira Pharmaceuticals (NASDAQ:PCRX): The stock opened at $37.73 on Wednesday but the bulls could not build on the opening and the stock topped out at $38.63 for the day. The stock traded down to $37.17 during the day, due to lack of any buying support eventually closed down at $37.49 with a loss of -1.55% for the day. The stock had closed at $38.08 on the previous day. The total traded volume was 835,781 shares.

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.